Best Timillidge Podcasts (2025)

Within this podcast, Improving Provider Confidence in Patient Identification and the Administration of Oncolytic Viral Therapy, Dr. Howard Kaufman and Dr. Anna C. Pavlick examine the patient and tumor characteristics that may make a patient with advanced melanoma a good candidate for oncolytic viral therapy with or without a checkpoint inhibitor.…

1
Mechanisms of Oncolytic Viral Therapy With Drs. Howard Kaufman and Kevin Harrington 18:17

Play Pause

4y ago18:17

18:17

Within this podcast, Mechanisms of Oncolytic Viral Therapy, Dr. Howard Kaufman and Professor Kevin Harrington review the rationale for the use of oncolytic viral therapies as monotherapy or in combination with checkpoint inhibitors for patients with advanced melanoma.By Howard Kaufman, MD, FACS

1
Overview of Oncolytic Viral Therapy – Focus on Melanoma With Drs. Howard Kaufman and Dmitriy Zamarin 15:25

4y ago15:25

15:25

Within this podcast, Overview of Oncolytic Viral Therapy – Focus on Melanoma, Dr. Howard Kaufman and Dr. Dmitriy Zamarin evaluate the latest advances regarding the use of oncolytic viral therapy for cancer management, particularly in the context of advanced melanoma.By Howard Kaufman, MD, FACS

1
Oncolytic Viral Therapy – A Look at the Latest Evidence With Drs. Howard Kaufman and Ann Silk 14:56

4y ago14:56

14:56

Within the podcast, Oncolytic Viral Therapy – A Look at the Latest Evidence, Dr. Howard Kaufman and Dr. Ann Silk assess the latest clinical evidence regarding available and emerging oncolytic viral therapies for the management of patients with advanced melanoma.By Howard Kaufman, MD, FACS

1
Updates in Newly-Diagnosed PTCL 14:02

5+ y ago14:02

14:02

Peripheral T-cell lymphomas (PTCLs) are a highly heterogeneous and typically aggressive group of non-Hodgkin lymphomas. Theses rare tumors represent only 10% to 15% of non-Hodgkin lymphomas and are associated with 5-year survival rates as low as 20% in certain subtypes. Treatment of PTCL has historically consisted of conventional chemotherapy. Howe…

1
Antibody-Drug Conjugates in PTCL 15:05

5+ y ago15:05

15:05

Peripheral T-cell lymphomas (PTCLs) are a highly heterogeneous and typically aggressive group of non-Hodgkin lymphomas. These rare tumors represent only 10% to 15% of non-Hodgkin lymphomas and are associated with 5-year survival rates as low as 20% in certain subtypes. Treatment of PTCL has historically consisted of conventional chemotherapy. Howev…

1
Options for Relapsed/Refractory PTCL 24:04

5+ y ago24:04

24:04

Peripheral T-cell lymphomas (PTCLs) are a highly heterogeneous and typically aggressive group of non-Hodgkin lymphomas. These rare tumors represent only 10% to 15% of non-Hodgkin lymphomas and are associated with 5-year survival rates as low as 20% in certain subtypes. Treatment of PTCL has historically consisted of conventional chemotherapy. Howev…

1
Updates in Diagnosis of PTCL and the Role of CD30 16:22

5+ y ago16:22

16:22

Peripheral T-cell lymphomas (PTCLs) are a highly heterogeneous and typically aggressive group of non-Hodgkin lymphomas. These rare tumors represent only 10% to 15% of non-Hodgkin lymphomas and are associated with 5-year survival rates as low as 20% in certain subtypes. Treatment of PTCL has historically consisted of conventional chemotherapy. Howev…

Timillidge Podcasts

1
MedEdTalks - Oncology

Owen A. O'Connor, MD

1
Case Studies on the Use of IO in NSCLC With Drs. Jeffrey Kern and Laurie Carr 24:26

1
Updates on the Use of Neoadjuvant and Adjuvant IO in Patients With NSCLC With Drs. Laurie Carr and Heather Wakelee 15:48

1
Updates in IO for Advanced NSCLC – Options for First-line Treatment and Management of Progressive Disease With Drs. Laurie Carr and Heather Wakelee 18:58

1
NSCLC: Updates in Testing and Interpreting Results – Focus on IO With Drs. Laurie Carr and David Ross Camidge 18:44

1
NSCLC: Optimizing Care Coordination – Through the Patient and Caregiver’s Eyes 27:59

1
Lung Cancer Advances and Challenges During a Pandemic – Where Do We Go From Here? With Drs. Jeffrey Kern and Charu Aggarwal 26:11

1
Improving Provider Confidence in Patient Identification and the Administration of Oncolytic Viral Therapy With Drs. Howard Kaufman and Anna Pavlick 15:35

1
Mechanisms of Oncolytic Viral Therapy With Drs. Howard Kaufman and Kevin Harrington 18:17

1
Overview of Oncolytic Viral Therapy – Focus on Melanoma With Drs. Howard Kaufman and Dmitriy Zamarin 15:25

1
Oncolytic Viral Therapy – A Look at the Latest Evidence With Drs. Howard Kaufman and Ann Silk 14:56

1
Updates in Newly-Diagnosed PTCL 14:02

1
Antibody-Drug Conjugates in PTCL 15:05

1
Options for Relapsed/Refractory PTCL 24:04

1
Updates in Diagnosis of PTCL and the Role of CD30 16:22